Obesity Market Potential Is Huge, But Access To Drugs An Increasing Challenge
Novo’s SELECT Readout For Wegovy May Answer Payer Questions
Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.
